Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile

IMMU : 22.58 (+0.04%)
Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Entergy Corporation (NYSE:ETR),...

PTCT : 30.01 (+1.28%)
ETR : 79.48 (+0.94%)
GES : 24.88 (+2.73%)
CHRW : 88.00 (+0.64%)
IMMU : 22.58 (+0.04%)
SNDR : 29.21 (+2.31%)
Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018

Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that it will host a conference call on Wednesday, May 9, 2018 at 5:00 p.m. Eastern Time to discuss third quarter fiscal...

IMMU : 22.58 (+0.04%)
Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher

Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

IMMU : 22.58 (+0.04%)
Today's Research Reports on Trending Tickers: Neuralstem and Immunomedics

NEW YORK, NY / ACCESSWIRE / April 11, 2018 / U.S. equities regained their footing on Tuesday, as trade tensions between the U.S. and China calmed after comments from the Chinese President Xi Jinping. The...

CUR : 1.68 (+0.60%)
IMMU : 22.58 (+0.04%)
Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer

Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leader in the field of antibody-drug conjugates (ADCs), today announced the appointment of Robert Iannone, M.D., M.S.C.E., as Head...

IMMU : 22.58 (+0.04%)
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference

Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at Cowen and Company...

IMMU : 22.58 (+0.04%)
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference

Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that Michael Pehl, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets...

IMMU : 22.58 (+0.04%)
Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside?

- Fennec Pharma's (FENC) lead drug sodium thiosulfate headed for U.S. FDA review in coming months and will likely be approved imminently based on strong Phase 3 trial results. Could generate $100-$200...

FOSL : 20.56 (+5.11%)
JAZZ : 163.58 (-0.83%)
IMMU : 22.58 (+0.04%)
Blog Exposure - FDA Accepts Amicus Therapeutics' NDA for Migalastat for Treatment of Fabry Disease

Stock Monitor: Immunomedics Post Earnings Reporting

FOLD : 15.93 (+5.08%)
IMMU : 22.58 (+0.04%)
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update

Presented Compelling Results with Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (mTNBC) at San Antonio Breast Cancer Symposium

IMMU : 22.58 (+0.04%)
New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cavco Industries, Inc. (NASDAQ:CVCO),...

CVCO : 178.75 (-0.69%)
CSCO : 43.57 (-0.25%)
NCOM : 45.80 (-0.49%)
PRSC : 73.50 (-0.57%)
EBS : 50.61 (-0.90%)
IMMU : 22.58 (+0.04%)
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer

Immunomedics to Fund Phase 2 Study Sponsored by the University of Wisconsin to Enable Further Investigation of Sacituzumab Govitecan in the Treatment of Patients with Castration-Resistant Prostate Cancer...

IMMU : 22.58 (+0.04%)
Today's Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics

NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Shares of Immunomedics soared to a new high yesterday after the company announced on Monday that it has agreed to sell tiered, sales-based royalty rights...

IMMU : 22.58 (+0.04%)
AXSM : 3.25 (-2.99%)
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million

Royalty Pharma acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU-132) Across All Indications for $175 Million

IMMU : 22.58 (+0.04%)
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities...

JPM : 111.23 (-1.12%)
IMMU : 22.58 (+0.04%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

IMMU : 22.58 (+0.04%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK , Dec. 13, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary...

IMMU : 22.58 (+0.04%)
Multi-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring Devices

Global revenues for the medical device market are already a multi-billion dollar industry and the sector aims to continue its growth through leverage created through mergers and acquisitions, as well as...

LNB.CN : 0.260 (unch)
NCI : 24.32 (+1.12%)
LXGTF : 0.2000 (-0.45%)
MDGL : 122.64 (+1.10%)
BEAT : 42.45 (+1.68%)
VTGN : 0.97 (-2.02%)
IMMU : 22.58 (+0.04%)
Today's Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Immunomedics soared yesterday after revealing positive data from a phase 2 study on its lead compound that could treat metastatic triple-negative breast...

VRX : 22.22 (+0.09%)
IMMU : 22.58 (+0.04%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar